Shares of Roche Holding AG fell after a poster highlighted side effects in an early-stage study of the Swiss pharmaceutical company’s experimental obesity medicine.
The poster, released as part of this week’s European Association for the Study of Diabetes annual meeting, showed side effects including nausea, vomiting and diarrhea for Roche’s injectable drug, CT-388. The stock fell as much as 4.5% in Zurich on Monday.